Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Hematologic Neoplasms 4Neutropenia 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma 2Leukemia 2Infections 2Fever 2Febrile Neutropenia 2Waldenstrom Macroglobulinemia 1Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Respiratory Distress Syndrome 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Arterial Hypertension 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia, Viral 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Diseases 1Pain 1

Interventions

gamma-Globulins 1chlorhexidine gluconate 1Standard of Care 1Saline Solution 1Probenecid 1Piperacillin, Tazobactam Drug Combination 1Levofloxacin 1Drug Therapy 1Cystectomy 1Chlorhexidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bacterial Infections × Piperacillin, Tazobactam Drug Combination × Clear all
NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
200 enrolled

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡